Reslizumab intravenous (IV) vs placebo
Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma
1 finding from 1 review
- no estimate extracted4 studies · 1652 participantsHigh
Findings
What do systematic reviews say?
1,822 questions · 1,891 findings · 321 reviews · Headline outcomes only
No studies found 279 · 14.8%GRADE not reported 46 · 2.4%Very low 524 · 27.7%Low 571 · 30.2%Moderate 330 · 17.5%High 141 · 7.5%
Reslizumab subcutaneous (SC) vs placebo
Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma
1 finding from 1 review
- no estimate extracted1 study · 464 participantsHigh
Reslizumab subcutaneous (SC) vs placebo
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with asthma
1 finding from 1 review
- no estimate extracted1 study · 464 participantsHigh
Mepolizumab subcutaneous (SC) vs placebo
Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma
1 finding from 1 review
- no estimate extracted3 studies · 1231 participantsHigh
Benralizumab subcutaneous (SC) vs placebo
Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma
1 finding from 1 review
- no estimate extracted4 studies · 2791 participantsHigh
Mepolizumab subcutaneous (SC) vs placebo
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with asthma
1 finding from 1 review
- no estimate extracted3 studies · 1231 participantsHigh
Binocular iPad treatment vs occlusion therapy
Visual acuity · 5‐ to 8‐year‐old children with amblyopia
2 findings from 1 review
- Binocular versus standard occlusion or blurring treatment for unilateral amblyopia in children aged three to eight years 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 63 participantsModerate
- Binocular versus standard occlusion or blurring treatment for unilateral amblyopia in children aged three to eight years 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 62 participantsModerate
Autologous myeloablative selective HSCT vs cyclophosphamide
FVC · people with systemic sclerosis
Autologous myeloablative selective HSCT showed no clear difference in interstitial lung disease – FVC (% predicted) A lower percentage… compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
- RR 1.63 [0.75, 3.51]1 study · 75 participantsModerate
Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide
Interstitial lung disease – FVC % predicted A lower percentage represents worse lung disease. The study incorporated a ≥ 15% chance · people with systemic sclerosis
1 finding from 1 review
- no estimate extracted1 study · 19 participantsLow
Autologous non‐myeloablative selective HSCT vs cyclophosphamide
Interstitial lung disease – FVC % predicted A lower percentage represents worse lung disease · people with systemic sclerosis
1 finding from 1 review
- no estimate extracted1 study · 131 participantsModerate
Summary of findings table ‐ Adjunctive therapies in addition to land‐based exercise therapy vs land‐based exercise therapy
Radiographic joint changes · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
- Adjunctive therapies in addition to land‐based exercise therapy for osteoarthritis of the hip or knee 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 156 participantsLow
Active rPMS only vs no intervention
Lower limb function · people with stroke
The review found no eligible studies for this question.
1 finding from 1 review
- Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Active rPMS plus rehabilitation vs sham rPMS plus rehabilitation
Lower limb function · people with stroke
The review found no eligible studies for this question.
1 finding from 1 review
- Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Active rPMS plus rehabilitation vs rehabilitation only
Lower limb function · people with stroke
The review found no eligible studies for this question.
1 finding from 1 review
- Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Active rPMS only vs sham rPMS
Lower limb function · people with stroke
The review found no eligible studies for this question.
1 finding from 1 review
- Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Family‐centred care vs control
Harms · Indigenous children aged < 5 years
1 finding from 1 review
- Family‐centred interventions for Indigenous early childhood well‐being by primary healthcare services 2022 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 2 participantsVery low
Whole‐facility changes: Home‐like models vs traditional environment
Global behaviour Neuropsychiatric Inventory (NPI), Neuropsychiatric Inventory‐Nursing Home version (NPI‐NH) and Nurses Observations Scale for Geriatric Patients (NOSGER) (lower scores = better) · older adults living in long‐term residential care including, but not limited to, dementia‐specific care settings
1 finding from 1 review
- Physical environmental designs in residential care to improve quality of life of older people 2022 · Cochrane Headline outcomes onlyno estimate extracted257 participantsVery low
Whole‐facility changes: Home‐like models vs traditional environment
Depression Revised Memory and Behaviour Problems Checklist (RMBPC) and Mood Scale Score (MSS) (lower scores = better) · older adults living in long‐term residential care including, but not limited to, dementia‐specific care settings
1 finding from 1 review
- Physical environmental designs in residential care to improve quality of life of older people 2022 · Cochrane Headline outcomes onlyno estimate extracted406 participantsVery low
Whole‐facility changes: Home‐like models vs traditional environment
Activities of daily living · older adults living in long‐term residential care including, but not limited to, dementia‐specific care settings
1 finding from 1 review
- Physical environmental designs in residential care to improve quality of life of older people 2022 · Cochrane Headline outcomes onlyno estimate extracted499 participantsVery low
Whole‐facility changes: Home‐like models vs traditional environment
Serious adverse effects Physical restraints, reported as percentage points (lower = better) · older adults living in long‐term residential care including, but not limited to, dementia‐specific care settings
It is very uncertain whether whole‐facility changes: Home‐like models changes serious adverse effects Physical restraints, reported as percentage… compared with traditional environment (very low certainty).
1 finding from 1 review
- Physical environmental designs in residential care to improve quality of life of older people 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 74449 participantsVery low